Effective Treatment with Cabozantinib in an Advanced Non-Small-Cell Lung Cancer Patient Harboring a CD74-ROS1 Fusion: A Case Report
Gang Wang, 1, 2,* Jinqi Gao, 3,* Jinyan Lv, 1 Xi Chen, 1 Jinyu Wu, 1 Ruoyu Wang, 1, 2 Jianing Jiang 1, 2 1Department of Medical Oncology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning Province, People’s Republic of China; 2The Key Laboratory of Biomarker, High-...
Main Authors: | Wang G, Gao J, Lv J, Chen X, Wu J, Wang R, Jiang J |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-02-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/effective-treatment-with-cabozantinib-in-an-advanced-non-small-cell-lu-peer-reviewed-article-OTT |
Similar Items
-
A patient with classic biphasic pulmonary blastoma harboring CD74–ROS1 fusion responds to crizotinib
by: Meng Z, et al.
Published: (2017-12-01) -
Construction of pcDNA3.1-CD74-ROS1 Recombinant Plasmid and Effect of CD74-ROS1 Expression on Proliferation and Migration of Lung Cancer Cells
by: WU Yazhou, et al.
Published: (2018-04-01) -
A case of lung adenocarcinoma with a novel CD74‐ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib
by: Mizuha Haraguchi Hashiguchi, et al.
Published: (2021-09-01) -
Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
by: Mehta A, et al.
Published: (2020-02-01) -
A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma
by: Lan S, et al.
Published: (2020-11-01)